Incidence and clinical outcomes of the different neovascular forms of age-related macular degeneration in Valencia (Spain).

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Monje-Fernandez L
  • Dolz-Marco R
  • Gallego-Pinazo R

Grupos

Abstract

OBJECTIVE: To analyse the incidence and outcomes of the different neovascular subtypes in age-related macular degeneration (AMD). MATERIAL AND METHODS: A retrospective review was carried out on patients with neovascular AMD treated in the University and Polytechnic Hospital la Fe in Valencia by the same retinal physician (RGP) between December 2012 and July 2015. The anatomic classification of the neovascular lesions was recorded, as well as the number of intravitreal treatments administered and the change in visual acuity (VA) obtained throughout the follow-up. RESULTS: A total number of 174 eyes of 156 patients (mean age: 79.9years) with a minimum follow-up of 4 months were included. The anatomic classification of choroidal neovascularisation (CNV) showed the presence of type1 lesions in 40,8%, type2 lesions in 12%, type3 lesions in 31%, and mixed lesions in 14.4%, with 1.7% showing polypoidal choroidal vasculopathy features. Overall, the mean baseline VA was 0,32, improving to 0,38 at 24months, after having received a mean of 9.3 injections. Type2, 3, and mixed forms showed a visual result significantly lower than type1, but there was no significant difference in the polypoidal vasculopathy. CONCLUSIONS: Type 1 CNV was the most common finding, and was associated with a better visual prognosis, compared to the other neovascular lesions.

Datos de la publicación

ISSN/ISSNe:
0365-6691, 1989-7286

Archivos de la Sociedad Espanola de Oftalmologia  Elsevier Ltd

Tipo:
Article
Páginas:
324-328
PubMed:
29580755
Factor de Impacto:
0,230 SCImago
Cuartil:
Q4 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Anatomic classification; Clasificacion anatomica; DMAE neovascular; Incidence; Incidencia; Neovascular AMD; Optical coherence tomography; Ranibizumab; Tomografia de coherencia optica

Cita

Compartir